Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy (Q43510996)

24 November 2017

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy (English)

1 reference

24 November 2017

fluticasone propionate

1 reference

1 reference

K T Kim

1

1 reference

24 November 2017

E J Ginchansky

2

1 reference

24 November 2017

B F Friedman

3

1 reference

24 November 2017

S Srebro

4

1 reference

24 November 2017

P J Pepsin

5

1 reference

24 November 2017

L Edwards

6

1 reference

24 November 2017

R H Stanford

7

1 reference

24 November 2017

K Rickard

8

1 reference

24 November 2017

1 November 2000

1 reference

Annals of Allergy, Asthma & Immunology

24 November 2017

1 reference

24 November 2017

85

1 reference

24 November 2017

5

1 reference

24 November 2017

398-406

1 reference

Inhaled steroids and the risk of hospitalization for asthma

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Structure-activity relationships of topically active steroids: the selection of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Should Antileukotriene Therapies Be Used Instead of Inhaled Corticosteroids in Asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Time to onset of effect of fluticasone propionate in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Increased nitric oxide in exhaled air of asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Glucocorticosteroids inhibit leukotriene production

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

The effect of inhaled budesonide on the maximal degree of airway narrowing to leukotriene D4 and methacholine in normal subjects in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962555-0

7 January 2021

10.1016/S1081-1206(10)62555-0

Identifiers

DOI

1 reference

24 November 2017

1 reference